Company / Cash per Share
Enliven Therapeutics, Inc. Cash per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$2.64
FY2024
5-year range
$2.23 / $24.18
FY2020-FY2024
Trend
-6.4%
vs FY2023
Sector context
#81 of 205
Health Care
What the data says
At $2.64, Enliven Therapeutics, Inc.'s cash per share ranks #81 of 205 in the Health Care sector. Declined from $24.18 to $2.64 over the past 2 years.
Based on SEC 10-K filings.
2.64 in FY2024 with a 5-year CAGR of -17.8%.
Declined from $24.18 to $2.64 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +5.7%
- 5-Year CAGR
- -17.8%
- 10-Year CAGR
- -
Sector benchmark
#81 of 205 in Health CareTop 40% of 205This company $2.64 Sector average $67.98
▼
-96.1% below sector average
Key checks
Key Insights
- In FY2024, cash per share decreased 6.4% year-over-year.
- Ranks #81 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2022.
- Lowest cash per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.64 | -6.4% |
| FY2023 | $2.82 | -88.3% |
| FY2022 | $24.18 | +984.1% |
| FY2021 | $2.23 | -34.9% |
| FY2020 | $3.43 | -51.3% |
| FY2019 | $7.03 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026